Label: VASOPRESSIN injection

  • NDC Code(s): 42367-570-22, 42367-570-87
  • Packager: Eagle Pharmaceuticals, Inc.
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated March 9, 2023

If you are a consumer or patient please visit this version.

    These highlights do not include all the information needed to use VASOPRESSIN INJECTION, safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.

    VASOPRESSIN Injection, for intravenous use
    Initial U.S. Approval: 2014


    • Vasopressin Injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. (1)


    • Dilute 20 units/mL multiple dose vial content with normal saline (0.9% sodium chloride) or 5% dextrose in water (D5W) to either 0.1 units per mL or 1 unit per mL for intravenous administration. Discard unused diluted solution after 18 hours at room temperature or 24 hours under refrigeration. (2.1)
    • Post-cardiotomy shock: 0.03 to 0.1 units/minute (2.2)
    • Septic shock: 0.01 to 0.07 units/minute (2.2)


    • Injection: 20 units per mL in a multiple dose vial. To be used after dilution. (3)


    • Vasopressin Injection is contraindicated in patients with known allergy or hypersensitivity to 8-L-arginine vasopressin or chlorobutanol. (4)


    • Can worsen cardiac function. (5.1)
    • Reversible diabetes insipidus. (5.2)


    The most common adverse reactions include decreased cardiac output, bradycardia, tachyarrhythmias, hyponatremia and ischemia (coronary, mesenteric, skin, digital). (6)

    To report SUSPECTED ADVERSE REACTIONS, contact Eagle Pharmaceuticals, Inc. at 1-855-318-2170 or FDA at 1-800-FDA-1088 or


    • Pressor effects of catecholamines and Vasopressin Injection are expected to be additive. (7.1)
    • Indomethacin may prolong effects of Vasopressin Injection. (7.2)
    • Co-administration of ganglionic blockers or drugs causing SIADH may increase the pressor response. (7.3, 7.4)
    • Co-administration of drugs causing diabetes insipidus may decrease the pressor response. (7.5)


    Pregnancy: May induce uterine contractions. (8.1)

    Pediatric Use: Safety and effectiveness have not been established. (8.4)

    Geriatric Use: No safety issues have been identified in older patients. (8.5)

    Revised: 6/2021

  • Table of Contents

    Vasopressin Injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.


    2.1 Preparation of Solution

    Inspect parenteral drug products for particulate matter and discoloration prior to use, whenever solution and container permit.

    Vasopressin Injection Solution for Dilution, 20 units/mL

    Dilute Vasopressin Injection in normal saline (0.9% sodium chloride) or 5% dextrose in water (D5W) prior to use for intravenous administration. Discard unused diluted solution after 18 hours at room temperature or 24 hours under refrigeration.

    Table 1 Preparation of diluted solutions
    Vasopressin InjectionDiluent
    No  0.1 units/mL  2.5 mL (50 units)500 mL
    Yes  1 unit/mL  5 mL (100 units)100 mL

    2.2 Administration

    In general, titrate to the lowest dose compatible with a clinically acceptable response.

    The recommended starting dose is:

    Post-cardiotomy shock: 0.03 units/minute

    Septic Shock: 0.01 units/minute

    Titrate up by 0.005 units/minute at 10- to 15-minute intervals until the target blood pressure is reached. There are limited data for doses above 0.1 units/minute for post-cardiotomy shock and 0.07 units/minute for septic shock. Adverse reactions are expected to increase with higher doses.

    After target blood pressure has been maintained for 8 hours without the use of catecholamines, taper vasopressin injection by 0.005 units/minute every hour as tolerated to maintain target blood pressure.


    Vasopressin injection, USP is a clear, practically colorless solution available as 20 units/mL in a multiple dose vial. To be used after dilution.


    Vasopressin Injection is contraindicated in patients with known allergy or hypersensitivity to 8-L-arginine vasopressin or chlorobutanol.


    5.1 Worsening Cardiac Function

    A decrease in cardiac index may be observed with the use of vasopressin.

    5.2 Reversible Diabetes Insipidus

    Patients may experience reversible diabetes insipidus, manifested by the development of polyuria, a dilute urine, and hypernatremia, after cessation of treatment with vasopressin. Monitor serum electrolytes, fluid status and urine output after vasopressin discontinuation. Some patients may require readministration of vasopressin or administration of desmopressin to correct fluid and electrolyte shifts.


    The following adverse reactions associated with the use of vasopressin were identified in the literature. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.

    Bleeding/lymphatic system disorders: Hemorrhagic shock, decreased platelets, intractable bleeding

    Cardiac disorders: Right heart failure, atrial fibrillation, bradycardia, myocardial ischemia

    Gastrointestinal disorders: Mesenteric ischemia

    Hepatobiliary: Increased bilirubin levels

    Renal/urinary disorders: Acute renal insufficiency

    Vascular disorders: Distal limb ischemia

    Metabolic: Hyponatremia

    Skin: Ischemic lesions

    Postmarketing Experience

    Reversible diabetes insipidus [see Warnings and Precautions (5.2)].


    7.1 Catecholamines

    Use with catecholamines is expected to result in an additive effect on mean arterial blood pressure and other hemodynamic parameters. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed.

    7.2 Indomethacin

    Use with indomethacin may prolong the effect of Vasopressin Injection on cardiac index and systemic vascular resistance. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed [see Clinical Pharmacology (12.3)].

    7.3 Ganglionic Blocking Agents

    Use with ganglionic blocking agents may increase the effect of Vasopressin Injection on mean arterial blood pressure. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed [see Clinical Pharmacology (12.3)].

    7.4 Drugs Suspected of Causing SIADH

    Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasopressin Injection. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed.

    7.5 Drugs Suspected of Causing Diabetes Insipidus

    Use with drugs suspected of causing diabetes insipidus (e.g., demeclocycline, lithium, foscarnet, clozapine) may decrease the pressor effect in addition to the antidiuretic effect of Vasopressin Injection. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed.


    8.1 Pregnancy

    Risk Summary
    There are no available data on Vasopressin Injection use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted.

    Clinical Considerations
    Dose adjustments during pregnancy and the postpartum period: Because of increased clearance of vasopressin in the second and third trimester, the dose of Vasopressin Injection may need to be increased [see Dosage and Administration (2.2) and see Clinical Pharmacology (12.3)].

    Maternal adverse reactions: Vasopressin Injection may produce tonic uterine contractions that could threaten the continuation of pregnancy.

    8.2 Lactation

    There are no data on the presence of vasopressin injection in either human or animal milk, the effects on the breastfed infant, or the effects on milk production.

    8.4 Pediatric Use

    Safety and effectiveness of Vasopressin Injection in pediatric patients with vasodilatory shock have not been established.

    8.5 Geriatric Use

    Clinical studies of vasopressin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see Warnings and Precautions (5), Adverse Reactions (6), and Clinical Pharmacology (12.3)].


    Overdosage with Vasopressin Injection can be expected to manifest as consequences of vasoconstriction of various vascular beds (peripheral, mesenteric, and coronary) and as hyponatremia. In addition, overdosage may lead less commonly to ventricular tachyarrhythmias (including Torsade de Pointes), rhabdomyolysis, and non-specific gastrointestinal symptoms.

    Direct effects will resolve within minutes of withdrawal of treatment.


    Vasopressin is a polypeptide hormone. Vasopressin Injection, USP is a sterile, aqueous solution of synthetic arginine vasopressin for intravenous administration.

    The 1 mL solution contains vasopressin 20 units per mL, chlorobutanol, NF 0.5% as a preservative, and Water for Injection, USP adjusted with acetic acid to pH 3.4 – 3.6.

    The chemical name of vasopressin is Cyclo (1-6) L-Cysteinyl-L-Tyrosyl-L-Phenylalanyl-L-Glutaminyl-L-Asparaginyl-L-Cysteinyl-L-Prolyl-L-Arginyl-L-Glycinamide. It is a white to off-white amorphous powder, freely soluble in water. The structural formula is:

    Chemical Structure

    Molecular Formula: C46H65N15O12S2          Molecular Weight: 1084.23

    One mg is equivalent to 530 units.


    12.1 Mechanism of Action

    Vasopressin causes vasoconstriction by binding to V1 receptors on vascular smooth muscle coupled to the Gq/11-phospholipase C-phosphatidyl-inositol-triphosphate pathway, resulting in the release of intracellular calcium. In addition, vasopressin stimulates antidiuresis via stimulation of V2 receptors which are coupled to adenyl cyclase.

    12.2 Pharmacodynamics

    At therapeutic doses exogenous vasopressin elicits a vasoconstrictive effect in most vascular beds including the splanchnic, renal and cutaneous circulation. In addition, vasopressin at pressor doses triggers contractions of smooth muscles in the gastrointestinal tract mediated by muscular V1-receptors and release of prolactin and ACTH via V3 receptors. At lower concentrations typical for the antidiuretic hormone vasopressin inhibits water diuresis via renal V2 receptors. In addition, vasopressin has been demonstrated to cause vasodilation in numerous vascular beds that are mediated by V2, V3, oxytocin and purinergic P2 receptors.

    In patients with vasodilatory shock vasopressin in therapeutic doses increases systemic vascular resistance and mean arterial blood pressure and reduces the dose requirements for norepinephrine. Vasopressin tends to decrease heart rate and cardiac output. The pressor effect is proportional to the infusion rate of exogenous vasopressin. The pressor effect reaches its peak within 15 minutes. After stopping the infusion the pressor effect fades within 20 minutes. There is no evidence for tachyphylaxis or tolerance to the pressor effect of vasopressin in patients.

    12.3 Pharmacokinetics

    Vasopressin plasma concentrations increase linearly with increasing infusion rates from 10 to 200 μU/kg/min. Steady state plasma concentrations are achieved after 30 minutes of continuous intravenous infusion.

    Distribution Vasopressin does not appear to bind plasma protein. The volume of distribution is 140 mL/kg.

    At infusion rates used in vasodilatory shock (0.01 to 0.1 units/minute), the clearance of vasopressin is 9 to 25 mL/min/kg in patients with vasodilatory shock. The apparent t1/2 of vasopressin at these levels is ≤10 minutes.

    Serine protease, carboxipeptidase and disulfide oxido-reductase cleave vasopressin at sites relevant for the pharmacological activity of the hormone. Thus, the generated metabolites are not expected to retain important pharmacological activity.

    Vasopressin is predominantly metabolized and only about 6% of the dose is excreted unchanged into urine.

    Specific Populations

    Pregnancy: Because of a spillover into blood of placental vasopressinase the clearance of exogenous and endogenous vasopressin increases gradually over the course of a pregnancy. During the first trimester of pregnancy, the clearance is only slightly increased. However, by the third trimester the clearance of vasopressin is increased about 4-fold and at term up to 5-fold. After delivery the clearance of vasopressin returns to preconception baseline within two weeks.

    Drug Interactions Indomethacin more than doubles the time to offset for vasopressin’s effect on peripheral vascular resistance and cardiac output in healthy subjects [see Drug Interactions (7.2)].

    The ganglionic blocking agent tetra-ethylammonium increases the pressor effect of vasopressin by 20% in healthy subjects [see Drug Interactions (7.3)].

    Halothane, morphine, fentanyl, alfentanyl and sufentanyl do not impact exposure to endogenous vasopressin.


    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    No formal carcinogenicity or fertility studies with vasopressin have been conducted in animals. Vasopressin was found to be negative in the in vitro bacterial mutagenicity (Ames) test and the in vitro Chinese hamster ovary (CHO) cell chromosome aberration test. In mice, vasopressin has been reported to have an effect on function and fertilizing ability of spermatozoa.

    13.2 Animal Toxicology and/or Pharmacology

    No toxicology studies were conducted with vasopressin.


    Increases in systolic and mean blood pressure following administration of vasopressin were observed in 7 studies in septic shock and 8 in post-cardiotomy vasodilatory shock.


    Vasopressin Injection, USP is a clear, colorless to practically colorless solution for intravenous administration available as:

    NDC 42367-570-87: A carton containing 25 x 1 mL multiple dose vials. Each vial contains vasopressin 1 mL at 20 units/mL.

    Store between 2°C and 8°C (36°F and 46°F). Do not freeze.

    Vials may be held up to 12 months upon removal from refrigeration to room temperature storage conditions (20°C to 25°C [68°F to 77°F], USP Controlled Room Temperature), anytime within the labeled shelf life. Once removed from refrigeration, unopened vial should be marked to indicate the revised 12 month expiration date. If the manufacturer’s original expiration date is shorter than the revised expiration date, then the shorter date must be used. Do not use Vasopressin Injection beyond the manufacturer’s expiration date stamped on the vial.

    Discard vial after 48 hours after first puncture.

    The storage conditions and expiration periods are summarized in the following table.

    Unopened Refrigerated
    2°C to 8°C (36°F to 46°F)
    Unopened Room Temperature 20°C to
    25°C (68°F to 77°F) Do not store above
    25°C (77°F)
    Opened (After First
    1 mL VialUntil manufacturer
    expiration date
    12 months or until manufacturer expiration
    date, whichever is earlier
    48 hours

    Marketed by:
    Eagle Pharmaceuticals, Inc.
    Woodcliff Lake, NJ 07677
    Rev. 06/2021
  • PRINCIPAL DISPLAY PANEL - NDC: 42367-570-87 - Vial Carton

    vial carton

  • PRINCIPAL DISPLAY PANEL - NDC: 42367-570-22 - Vial Label

    vial label

    vasopressin injection
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:42367-570
    Route of AdministrationPARENTERAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    ACETIC ACID (UNII: Q40Q9N063P)  
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:42367-570-8725 in 1 CARTON01/10/202206/30/2024
    1NDC:42367-570-221 mL in 1 VIAL, MULTI-DOSE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    Labeler - Eagle Pharmaceuticals, Inc. (849818161)
    NameAddressID/FEIBusiness Operations
    Curia New Mexico, LLC078268825MANUFACTURE(42367-570) , ANALYSIS(42367-570)